• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Unproven Treatments

Background

Because there is no cure for ALS/MND, and approved treatments have a limited effect, people diagnosed with the disease may seek out options that are not offered by their physician. Determining the difference between true and false information regarding ALS treatments can be difficult.

The internet has many websites that promote effective ALS treatments for purchase. Often they are well designed, boast treatments available for multiple diseases and ailments, and provide reassurance through online testimonials from previous clients. In nearly all of these cases, there is no evidence of safety, and in none has a benefit been shown in rigorous scientific studies. Furthermore, these treatments are often extremely expensive, and they are marketed to people who are looking for options. Many people with ALS spend critical life savings or raise funds through family and friends for an opportunity to save their life.

Unproven treatments are sometimes called alternative or off-label treatments. Examples include, but are not limited to: stem cell clinics; holistic, naturopathic, homeopathic, and traditional medicine; and dietary or physical therapy regimens.

Resources like ALSUntangled can be valuable for balanced, open-access information about such alternative treatments, and ClinicalTrials.gov is a resource for determining whether a particular treatment is being tested in a legitimate clinical trial.

The ALSUntangled article “Ten red flags”—things to be wary of in alternative or off-label products—provides a helpful guide to the warning signs to look out for in an advertised potential treatment. Read the “Ten red flags” article.

Recommendation

The SAC recommends that Alliance members defer all medical advice regarding unapproved, unproven, or off-label treatments to an individual’s own clinician. This may be accompanied by objective information about the specific treatment, which may be provided by the SAC. Providing links to resources like ALSUntangled and clinical trials databases like ClinicalTrials.gov is encouraged. Accompanying information can be especially important in situations where an individual does not have access to an ALS specialist physician, and it may assist their clinician in making a medical recommendation. It can also be important to relay that there are thousands of researchers around the world who are dedicated to understanding ALS and finding effective treatments, and if there were anything, anywhere, that actually worked, we would know and we would do everything we could to get it to people living with the disease as soon as possible.

International Alliance of ALS/MND Associations
June 2020


The original language of communication is English, and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Advocacy

  • Advocacy Toolkit

  • Angelique van der Lit-van Veldhuizen, Netherlands

    Angelique van der Lit-van Veldhuizen, Netherlands

  • Manuel Arn, Switzerland

    Manuel Arn, Switzerland

  • Chirag Walia, India

    Chirag Walia, India
    ChiragWalia

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • Margarita Pizarro, Argentina

    Margarita Pizarro, Argentina

  • Hiroshi Matsuyama, Japan

    Hiroshi Matsuyama, Japan

  • Karl Hughes, Ireland

    Karl Hughes, Ireland

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • Mike Rannie, Canada

    Mike Rannie, Canada

  • Frank Bos, Netherlands

    Frank Bos, Netherlands

  • Sébastien Batiot, France

    Sébastien Batiot, France

  • Oscar Mauricio Linares, Colombia

    Oscar Mauricio Linares, Colombia

  • Steve

    Steve

  • Emilienne Verhaegen, Belgium

    Emilienne Verhaegen, Belgium

  • Chris McCauley, Canada

    Chris McCauley, Canada

  • Danny Reviers, Belgium

    Danny Reviers, Belgium

  • Anthony Lynch, Australia

    Anthony Lynch, Australia

  • Jon Newsome, USA

    Jon Newsome, USA

  • Patrick Shuma, Kenya

    Patrick Shuma, Kenya

  • Aida Trzmiel de Guterman, Argentina

    Aida Trzmiel de Guterman, Argentina

  • Sam Hayden-Harler, UK

    Sam Hayden-Harler, UK

  • Carlos Gomez Matallanas, Spain

    Carlos Gomez Matallanas, Spain

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Chen Chun-Chin, Malaysia

    Chen Chun-Chin, Malaysia

  • Ywan Dierick, Belgium

    Ywan Dierick, Belgium

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Liam Dwyer, England

    Liam Dwyer, England

  • Barry de Reuver, Netherlands

    Barry de Reuver, Netherlands

  • Ana Lilia Rodriguez, Mexico

    Ana Lilia Rodriguez, Mexico

  • Elkin Ramiro Gaviria Muñoz, Colombia

    Elkin Ramiro Gaviria Muñoz, Colombia

  • Liong Ting Ngu, Malaysia

    Liong Ting Ngu, Malaysia

  • Fernando Ocampo Cardona, Colombia

    Fernando Ocampo Cardona, Colombia

  • Cath Muir, UK

    Cath Muir, UK
    Cath

  • Steven Gallagher, Canada

    Steven Gallagher, Canada

  • Brian Parsons, Canada

    Brian Parsons, Canada

  • Jose Rivero Muñoz, Mexico

    Jose Rivero Muñoz, Mexico

  • Fabio Carvalho, Brazil

    Fabio Carvalho, Brazil

  • Len Johnrose, England

    Len Johnrose, England

  • Mahmood Anwar, UK

    Mahmood Anwar, UK

  • Ian Gale, Australia

    Ian Gale, Australia

  • Ada Garrido Benavidez, Mexico

    Ada Garrido Benavidez, Mexico

  • Wendy Hendrickson, USA

    Wendy Hendrickson, USA

  • Zelina Brito, Brazil

    Zelina Brito, Brazil

  • Roxana Canova, Argentina

    Roxana Canova, Argentina

  • Francisco Perez Palop, Spain

    Francisco Perez Palop, Spain

  • Enzo Maccarrone, Italy

    Enzo Maccarrone, Italy

  • Danny Reviers, Belgium

    Danny Reviers, Belgium
    DannyReviers

  • Jorge Luis Fernández Romero, Mexico

    Jorge Luis Fernández Romero, Mexico

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login